Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | CASP2 | P42575 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.34 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.34 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.33 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.33 |
| ▸ | NAAA | Q02083 | 1/20 | 0.33 |
| ▸ | ALB | P02768 | 1/20 | 0.33 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16409459 | 0.88 | CASP2 (0.51) | MEN1KMT2AEPHX1CASP2MTNR1A | |
| SCHEMBL21913856 | 0.88 | ALDH1A1 (0.43) | MEN1KMT2ACASP2NAAAALB | |
| SCHEMBL12919637 | 0.86 | MEN1 (0.55) | MEN1KMT2AEPHX1RECQLALB | |
| SCHEMBL14952664 | 0.85 | ALDH1A1 (0.41) | MEN1KMT2ACASP2NAAAALB | |
| SCHEMBL16231519 | 0.84 | KDM4E (0.48) | EPHX1SIRT6SIRT1MTNR1AMTNR1B | |
| SCHEMBL25590403 | 0.84 | FOLH1 (0.37) | MEN1KMT2AEPHX1SIRT6SIRT1 | |
| SCHEMBL12055210 | 0.84 | KDM4E (0.48) | EPHX1SIRT6SIRT1MTNR1AMTNR1B | |
| SCHEMBL25129545 | 0.84 | ALDH1A1 (0.37) | MEN1KMT2AEPHX1CASP2NAAA | |
| SCHEMBL16248536 | 0.84 | NAMPT (0.40) | MEN1KMT2ACASP2NAAAALB | |
| SCHEMBL20729996 | 0.84 | ALB (0.38) | MEN1KMT2AEPHX1CASP2NAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8138305-B2 | Glucagon-like peptide-1 (glp-1) receptor agonist; diabetes, obesity, glucagonomas, secretory disorders of the airway, metabolic disorder, arthritis, osteoporosis, central nervous system disease, restenosis and neurodegenerative disease. | IPSEN PHARMA S.A.S. (FR) | 2012-03-20 | — | — | US | disclosed |
| US-7977455-B2 | Analogues of GLP-1 | IPSEN PHARMA, S.A.S. (FR) | 2011-07-12 | — | — | US | disclosed |
| US-7897566-B2 | Analogues of GLP-1 | IPSEN PHARMA S.A.S. (FR) | 2011-03-01 | — | — | US | disclosed |
| US-20100256056-A1 | ANALOGUES OF EXENDIN-4 AND EXENDIN-3 | IPSEN PHARMA S.A.S. (FR) | 2010-10-07 | — | — | US | disclosed |
| US-20090197802-A1 | Analogues of GLP-1 | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES, S.A.S. (FR) | 2009-08-06 | — | — | US | disclosed |
| US-20090149378-A1 | GLP-1 ANALOGUES | BIOMEASURE, INCORPORATED (US) | 2009-06-11 | — | — | US | disclosed |
| US-20080108566-A1 | Analogues of GLP-1 | IPSEN PHARMA S.A.S. (FR) | 2008-05-08 | — | — | US | disclosed |
| US-7268213-B2 | Analogues of GLP-1 | SOCIETE DE CONSELIS DE RECHERCHES ET D'APPLICATIONS SCIENTITIQUES, S.A.S. (FR) | 2007-09-11 | — | — | US | disclosed |
| US-20070042952-A1 | Analogues of glp-1 | IPSEN PHARMA S.A.S. (FR) | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090197802-A1 | Analogues of GLP-1 | GLP1R, IAPP, GIPR | MEN1 170/4885KMT2A 4224/4885EPHX1 3796/4885 |
| US-20070042952-A1 | Analogues of glp-1 | GLP1R, IAPP, GIPR | MEN1 281/4885KMT2A 4738/4885EPHX1 3965/4885 |
| US-20080108566-A1 | Analogues of GLP-1 | GLP1R, IAPP, GIPR | MEN1 170/4885KMT2A 4224/4885EPHX1 3796/4885 |
| US-20090149378-A1 | GLP-1 ANALOGUES | GLP1R, IAPP, GIPR | MEN1 158/4885KMT2A 4500/4885EPHX1 3608/4885 |
| US-20100256056-A1 | ANALOGUES OF EXENDIN-4 AND EXENDIN-3 | GLP1R, IAPP, MC4R | MEN1 125/4885KMT2A 3245/4885EPHX1 1614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.